News & Updates

The old immunomodulatory drug antithymocyte globulin (ATG), administered at a low dose, can safely reduce the loss of beta-cell function in young people with recent-onset type 1 diabetes (T1D), as shown in the phase II MELD-ATG trial.

Higher levels of oxidative balance score (OBS) are associated with a lower risk of advanced cardiovascular‒kidney‒metabolic (CKM) syndrome, reveals a study.

Treatment with the novel cannabinoid receptor 1 (CB1R) inverse agonist monlunabant appears to yield significant and clinically meaningful weight loss in adults with obesity and metabolic syndrome, according to a phase IIa trial.

The presence of both sarcopenia and obesity compounds the risks of frailty, functional decline, cognitive impairment, and mobility limitations compared with either condition alone, according to a study from Singapore.

Obesity during childhood appears to have an impact on penile growth, while obesity in adulthood influences the appearance of the penis rather than its actual size, reveals a study.